Barbiturate, Urine
Initially discovered in the early 20th century, barbiturates are one of the oldest classes of CNS depressants. Due to their low therapeutic index and high potential for abuse, barbiturates have generally been replaced by benzodiazepines, which are considered much safer. However, there are a wide variety of barbiturates present today and they are used mainly as sedatives, hypnotics, anticonvulsants, for migraine therapy, and the reduction of cerebral edema secondary to head injury.
Barbiturates are classified based on their duration of action, which is not necessarily correlated to their elimination half-lives. The ultrashort-acting barbiturates are extremely potent for a short period of time, such as thiopental, thiamylal, and methohexital and are used to induce surgical anesthesia. The short and intermediate-acting barbiturates include pentobarbital, secobarbital amobarbital, butalbital, aprobarbital, and butabarbital and are used as sedative-hypnotic agents. Pentobarbital has also been used to relieve intracranial pressure in head trauma cases. Phenobarbital is one of the long-acting barbiturates and is mainly used for its anticonvulsant property. The various classes of barbiturates also exhibit different, but overlapping, half-lives and some half-lives are dose dependent such as amobarbital.
Barbiturates can be administered either orally or parentally. Barbiturates undergo extensive hepatic metabolism. The intravenous route of administration is used to administer the ultrashort-acting barbiturates for induction of anesthesia. Barbiturates can elicit the following side effects: amnesia, hostility, irritability, Stevens-Johnson syndrome and vivid or disturbing dreams. Overdose effects include shallow respiration, clammy skin, dilated pupils, incoordination, slow speech, impaired thinking, bradycardia, tachycardia, coma, and possible death.
Numerous methods are available to screen for barbiturate use. Generally, immunoassays are used with antibodies that are directed toward secobarbital, and thus rely on degrees of cross-reactivity to the remaining drugs or active metabolites. Confirmation testing can be performed by a variety of analytical methods such Gas Chromatography/Mass Spectroscopy (GC/MS) and Liquid Chromatography/Mass Spectroscopy (LC/MS).
- Therapeutic monitoring in blood samples
- Drug abuse evaluation
- Toxicity assessment in blood samples
- Patient Compliance
Therapeutic levels
Short-acting: 0.5-2mg/L
Intermediate-acting: 1-5mg/L
Phenobarbital as sedative hypnotic: 5-15 mg/L
Treating seizures: 15-40 mg/L
Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.
Cut-Off Ranges
Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is a qualitative method such as immunoassay, or a quantitative method such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report.
Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.
Stability
- Ambient: 3 days
- Refrigerated: 14 days
- Frozen: 14 days
- J Addict Dis. 2010 Oct;29(4):436-48. [PMID: 20924879]
- Ann Clin Biochem. 1997 Sep;34 ( Pt 5):460-510. [PMID: 9293303]
- Cochrane Database Syst Rev. 2012 Jul 11;7:CD007139. [PMID: 22786504]
- Eur J Drug Metab Pharmacokinet. 1982;7(3):191-6. [PMID: 7173273]
- Urine Testing for Drug Abuse. National Institute on Drug Abuse (NIDA) Research Monograph. 1986;73.
- Baselt RC, Ed. Analytical Procedures for Therapeutic Drug Monitoring and Emergency Toxicology, 2nd ed. Littleton, MA: PSG Publishing Co. (1987).
- Principles of Forensic Toxicology, Fourth Edition, Ed, Barry Levine. AACC Press, Washington DC. Chapter 14, Benzodiazepines, pp. 237-251, (2013).
- Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, Eds. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill Co. (1996).
- Baselt RC, Ed. Disposition of Toxic Drugs and Chemicals in Man, 6th ed. Foster City, CA: Biomedical Publications (2002).
- Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7): 169-79
- Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4): 7-20.